Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer.

Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer.

http://www.wikidata.org/entity/Q37260377

about

Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer Novel therapeutic targets for pancreatic cancer E-cadherin's dark side: possible role in tumor progression Human correlates of provocative questions in pancreatic pathology DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells: a rare case report and review of the literature pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells.Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels Collagen XV inhibits epithelial to mesenchymal transition in pancreatic adenocarcinoma cells.Pathology and molecular genetics of pancreatic neoplasms.RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia.Molecular signatures of pancreatic cancer.GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1.Establishment and characterization of a novel primary hepatocellular carcinoma cell line with metastatic ability in vivo Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells Molecular characteristics of pancreatic ductal adenocarcinoma Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas.Genomic landscapes of pancreatic neoplasia.Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival Pathological and molecular evaluation of pancreatic neoplasms.Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition.Co-Expression of TWIST1 and ZEB2 in Oral Squamous Cell Carcinoma Is Associated with Poor Survival Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2.Integrin alpha2 mediates selective metastasis to the liver.Polycomb and the emerging epigenetics of pancreatic cancer.DNA methylation: its role in cancer development and therapy.DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells Epigenetics and epigenetic alterations in pancreatic cancer.The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting.Significance of the hedgehog pathway-associated proteins Gli-1 and Gli-2 and the epithelial-mesenchymal transition-associated proteins Twist and E-cadherin in hepatocellular carcinoma.Frizzled-2: A potential novel target for molecular pancreatic cancer therapy.miR-203 inhibits augmented proliferation and metastasis of hepatocellular carcinoma residual in the promoted regenerating liver Molecular pathogenesis of pancreatic cancer and clinical perspectives.Adenocarcinoma of the pancreas E-cadherin's role in development, tissue homeostasis and disease: Insights from mouse models: Tissue-specific inactivation of the adhesion protein E-cadherin in mice reveals its functions in health and disease.Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line.

P2860

Q24299591-F5A2F93A-ED0A-456F-88BF-343B5B92FA7B Q24564267-C0B7A339-D525-4C14-A903-9E4E7222E698 Q26865483-365A70D8-BF41-47A2-BE86-CF531BC5E38F Q27023576-F1939EF3-B465-461F-B54E-57D186B62463 Q27851466-7513AAB5-8DEA-4E92-97A5-9976113B5263 Q28083018-0025B33C-DE12-4C08-BF4E-8BBD73444F38 Q28476402-E7F8F1DB-B801-447C-A7BA-6DFD9631C1D6 Q28482104-30C471C3-6496-4BDD-B7A2-70B6BBCF78D3 Q30489093-54D2C2FB-6A14-4161-8E92-D29975C5D080 Q30502172-FD52D939-2D4F-4447-8E9F-A93BAE5D8DB2 Q31132591-B27BA349-360C-428E-9420-FB3028D79E5C Q33581119-E98B533D-A7B9-475D-830E-0C54416DA6C3 Q33719861-4E8075E6-461E-4D8F-96E7-00801D0F67F1 Q33918801-7320F81C-87D4-474D-860D-2BA47152A90F Q33979677-62C9B315-1B9E-4B70-8D24-820486CC50CC Q34402163-84F0EF6D-6FD6-45D4-8015-F06D93412961 Q34529319-E90C31D8-8FF7-4C10-8C27-4211763E1FB1 Q34621614-4CD0B7CF-78E4-4CD1-B113-EB2F6A9DDC33 Q34745252-D426EC34-347C-4053-9D8D-AEE0F1603295 Q34806852-0C9D8E59-3C14-48FF-8788-433C0F86FA71 Q35161198-FA98ACC4-C5B7-4DB1-82A1-D3CD935BA98D Q35170720-9F44DF97-EFD6-4685-A63E-1F37AE4606DF Q35177885-C7E42FC4-1647-454A-BAC0-AA2B2644773A Q35670143-DBF043FE-7093-4C23-9A60-D33957DDA039 Q35694314-F126A883-49A1-41B1-AF0A-39FE231CE57B Q35716304-BB057C59-178E-4B98-B562-D427DC3D8D22 Q35986433-D51AD4EE-99EB-41F6-8F0E-CE7F92365BCE Q36871177-D8F141FF-5C89-47D4-B9BF-6DCF90CDA0A2 Q36918656-D436ABA1-01C3-4D7D-9E5C-EC4FD56B752F Q36986433-A059BEAC-A4E5-4E4C-901A-42084990BCCC Q37016577-50E3E909-1C70-4E4A-BAEA-CF48FF1C54D5 Q37041763-FF20ABFF-DFD9-48FD-9B7D-BC90E05A24C7 Q37156381-C30ECF2F-3E37-41D3-B757-A167B7FB3BB8 Q37204746-1DF99504-36C5-4777-8BC7-C5C18E74CE51 Q37388659-D25114CF-477A-4432-98BF-C552887B687B Q37735613-0D868B94-A0B8-4A57-BAA3-2364C15B3EB4 Q37960816-01C9E813-85B6-4A0C-A7EC-782FA4EC1AD1 Q38274043-B27235B1-B0F3-4ABD-94F7-6AAE53851CCE Q38275614-69A9E964-C3FA-4989-92DD-1FADF0DA4AA2 Q38765553-C7A4341A-2E6A-43D1-9DFB-AF4EAA8AF6E3

P2860

Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer.

http://www.wikidata.org/entity/Q37260377

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Absence of E-cadherin expressi ...... om cohesive pancreatic cancer.

@en

Absence of E-cadherin expressi ...... om cohesive pancreatic cancer.

@nl

type

label

Absence of E-cadherin expressi ...... om cohesive pancreatic cancer.

@en

Absence of E-cadherin expressi ...... om cohesive pancreatic cancer.

@nl

prefLabel

Absence of E-cadherin expressi ...... om cohesive pancreatic cancer.

@en

Absence of E-cadherin expressi ...... om cohesive pancreatic cancer.

@nl

P1433

Q37260377-CAE0A16A-A296-4706-89D5-A16CFB376913

P1476

Q37260377-1AEAA4A8-9301-452F-9871-4CA2D0210548

P2093

Q37260377-2D71A231-11B5-4B6D-8D12-86221E536075

Q37260377-40E88F52-ED7C-431A-9535-90365918DF9D

Q37260377-42E77733-6446-413E-B9BF-7B832FD7FD5C

Q37260377-5B6091DB-23BB-4851-8C5E-C09618CE62C6

Q37260377-8DF08EDE-2A63-4351-92FF-1DA2CA4BD421

P2860

Q37260377-0FFC7070-801C-4D86-BCB4-3037AF0899FC

Q37260377-11C3C795-E760-43C6-8115-0897165C1C57

Q37260377-2A8FA779-82A5-4044-840C-62411B290599

Q37260377-2F8B43A5-DE85-4DCD-AD6A-0CE9EF10BB52

Q37260377-38719A63-74FE-4683-A9FB-16A4B771A64F

Q37260377-3DFC977A-1E49-4AB8-BE85-3114226F19D7

Q37260377-407933E3-83D9-44C4-9F46-C686AB5A23AF

Q37260377-48602A64-43E0-4E92-AB5C-EE864E964D4D

Q37260377-51318D00-7420-41FE-A4C8-CEDB18A33EAA

Q37260377-552C2C14-DC45-4BFC-8CE8-018919AC54A9

P304

Q37260377-9C23E690-88D7-4A98-B8AE-18DBBAB5B49E

P31

Q37260377-AF044D89-B3C4-4D29-8D36-0289CD5E987E

P356

Q37260377-48DAC9FC-A6E2-47FE-9938-0A98A46E6A62

P407

Q37260377-9F790293-61D8-4C04-8C55-E4DF946CB461

P433

Q37260377-2D5FE50A-9008-4B02-848A-4ABC66475775

P478

Q37260377-E44F2A7F-F998-4239-AAC3-F36D4D817C78

P50

Q37260377-4FEF7E3B-31AF-44D1-90C5-01DFEE7AF68E

Q37260377-EB9B491B-2C19-41B6-BF8F-524906B96F20

Q37260377-FEFBF740-2A5E-41D4-8590-CD58FCCFB442

P577

Q37260377-491ADFE9-F276-40AB-8139-F391BA891197

P698

Q37260377-D6F0D6AF-AC42-49DF-B22C-368B68125D5B

P932

Q37260377-A30FE226-D5D3-44FD-9AD1-E0642428B1D0

P356

1078-0432.CCR-07-0487

P1433

Clinical Cancer Research

P1476

Absence of E-cadherin expressi ...... rom cohesive pancreatic cancer

@en

P2093

Angela H Ting

http://www.w3.org/2001/XMLSchema#string

Eike Gallmeier

http://www.w3.org/2001/XMLSchema#string

Jordan M Winter

http://www.w3.org/2001/XMLSchema#string

Scott E Kern

http://www.w3.org/2001/XMLSchema#string

Steve B Baylin

http://www.w3.org/2001/XMLSchema#string

P2860

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression

Epithelial-mesenchymal transitions in development and pathologies

DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1

E-cadherin gene mutations in signet ring cell carcinoma of the stomach.

Adenocarcinoma of the distal bile duct. A clinicopathologic outcome analysis after curative resection.

Genetic progression in the pancreatic ducts.

A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature.

Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.

Epigenetic versus genetic alterations in the inactivation of E-cadherin.

P304

412-418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-0487

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Ralph H. Hruban

Felip Vilardell

Christine A Iacobuzio-Donahue

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18223216

http://www.w3.org/2001/XMLSchema#string

P932

3810144

http://www.w3.org/2001/XMLSchema#string